Merrimack Pharmaceuticals, Inc. (MACK) Financials

MACK Assets vs Liabilities

DateAssetsLiabilities
2023-12-31 19.2 million 441000
2023-09-30 19.3 million 493000
2023-06-30 19.4 million 411000
2023-03-31 19.6 million 463000

MACK Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-12-31 -295000 48000
2023-09-30 -203000 48000
2023-06-30 -668000 47000
2023-03-31 -356000 17000

MACK Net Income

No data available :(

MACK Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-12-31 18.9 million - -
2023-09-30 18.9 million - -
2023-06-30 19.0 million - -
2023-03-31 19.4 million - -

MACK Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-12-31 14.3 million
2023-09-30 14.3 million
2023-06-30 14.3 million
2023-03-31 14.3 million

MACK Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-12-31 - - 490000 -
2023-09-30 - - 531000 -
2023-06-30 - - 569000 -
2023-03-31 - 139000 586000 -

MACK Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-12-31 - -
2023-09-30 - -
2023-06-30 - -
2023-03-31 - -

MACK

Price: $15

52 week price:
11.53
15.89

Earnings Per Share: -0.08 USD

P/E Ratio: -138

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Volume: 32078

Ebitda: -5.0 million

Market Capitalization: 213.8 million

Links: